

AMENDMENTSIN THE SPECIFICATION:

Please replace the specification with the enclosed substitute specification.

IN THE CLAIMS:

✓ Please cancel original claims 12-14.

Please amend the claims as follows:

- 09855886-051501
1. (amended) A method for inhibiting angiogenesis in a mammal in need thereof comprising administering to the mammal a monoclonal antibody or antigen-binding fragment thereof which acts as an antagonist of the integrins GPIIb/IIIa($\alpha_{IIb}\beta_3$) and $\alpha_v\beta_3$ in an amount effective to inhibit angiogenesis in said mammal.
 2. (amended) The method according to claim 1, in which the antigen-binding fragment is an Fab, Fab', or F(ab')₂ fragment or derivative thereof. ?
 3. (amended) The method according to claim 1, in which the monoclonal antibody is selected from the group consisting of monoclonal antibody 7E3, produced by the ATCC 8832 hybridoma cell line and a murine/human chimeric monoclonal antibody or antigen-binding fragment thereof comprising the Fab region of monoclonal antibody 7E3.
- mb
B2